KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Current Deferred Revenue (2016 - 2017)

Historic Current Deferred Revenue for Acadia Pharmaceuticals (ACAD) over the last 8 years, with Q1 2017 value amounting to $4.1 million.

  • Acadia Pharmaceuticals' Current Deferred Revenue changed N/A to $4.1 million in Q1 2017 from the same period last year, while for Mar 2017 it was $4.1 million, marking a year-over-year change of. This contributed to the annual value of $2.6 million for FY2016, which is N/A changed from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Current Deferred Revenue stood at $4.1 million for Q1 2017.
  • In the past 5 years, Acadia Pharmaceuticals' Current Deferred Revenue registered a high of $4.1 million during Q1 2017, and its lowest value of $15000.0 during Q3 2014.
  • Its 4-year average for Current Deferred Revenue is $876090.9, with a median of $111000.0 in 2013.
  • The largest annual percentage gain for Acadia Pharmaceuticals' Current Deferred Revenue in the last 5 years was 6992.48% (2013), contrasted with its biggest fall of 8732.72% (2013).
  • Quarter analysis of 4 years shows Acadia Pharmaceuticals' Current Deferred Revenue stood at $55000.0 in 2013, then tumbled by 72.73% to $15000.0 in 2014, then skyrocketed by 17526.67% to $2.6 million in 2016, then soared by 56.28% to $4.1 million in 2017.
  • Its last three reported values are $4.1 million in Q1 2017, $2.6 million for Q4 2016, and $1.9 million during Q3 2016.